Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 20/20 | 0.54 |
| ▸ | TPH2 | Q8IWU9 | 10/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969787 | 1.00 | TPH1 (0.54) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL307950 | 0.85 | TPH1 (0.63) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL307902 | 0.85 | TPH1 (0.63) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL870175 | 0.83 | TPH1 (0.53) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL610006 | 0.83 | TPH1 (0.79) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL610005 | 0.83 | TPH1 (0.79) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL610004 | 0.83 | TPH1 (0.79) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL613496 | 0.81 | TPH1 (0.60) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL1332732 | 0.81 | TPH1 (0.60) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL613497 | 0.81 | TPH1 (0.60) | TPH1TPH2F2ESR1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9717727-B2 | Methods of treating and preventing leukemia and other cancers of the blood and bone | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-01 | — | — | US | disclosed |
| US-20140303197-A1 | METHODS OF TREATING AND PREVENTING LEUKEMIA AND OTHER CANCERS OF THE BLOOD AND BONE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2013074889-A1 | METHODS OF TREATING AND PREVENTING LEUKEMIA AND OTHER CANCERS OF THE BLOOD AND BONE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303197-A1 | METHODS OF TREATING AND PREVENTING LEUKEMIA AND OTHER CANCERS OF THE BLOOD AND BONE | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885F2 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.